Prostate cancer patients usually carry the TMPRSS2/ERG (T/E) fusion gene, and T/E can activate the NF-κB pathway through phosphorylation of NF-κB p65 Ser536 (p536) to promote the occurrence and development of prostate cancer [19]. Here, ERG is linked to prostate carcinoma.